A novel human Streptomyces strain redresses malignancy by inducing apoptosis and regaining gut homeostasis.

A novel human gut-derived Streptomyces strain, CGMCC 17111, significantly suppresses colorectal cancer by inducing apoptosis and restoring gut balance, with potent effects observed in vitro and in vivo.

• Why it matters: Colorectal cancer remains highly deadly due to limited effective treatments and issues like drug resistance and recurrence. Understanding and harnessing gut microbiota may offer new therapeutic avenues to improve outcomes and maintain host health.
• What they did: Researchers isolated and characterized CGMCC 17111, a distinct Streptomyces species from the human gut, demonstrating its ability to counteract tumor growth without causing harmful inflammation through genetic, phenotypic, and functional analyses.
• The result: This strain’s antitumor activity suggests potential for developing microbiota-based therapies that target malignancies while preserving gut homeostasis, opening new paths for cancer treatment strategies.